Primary prevention
Preventive approaches are primarily of use in the case of Fanconi syndrome secondary to toxin exposure. Lead and cadmium exposure are recognised risks, and the use of and exposure to both is regulated by law. Changes in tetracycline manufacture have been introduced to reduce its role in generating the syndrome. Cisplatin is now given at lower doses than in the past, and volume expansion is used to reduce renal exposure to the drug. Patients with hereditary sensitivity to particular carbohydrates can be protected from Fanconi syndrome by avoidance of the offending agents. New formulations of amphotericin B can reduce nephrotoxicity, with liposomal amphotericin B associated with significantly lower creatinine levels than conventional amphotericin B.[122]
Use of this content is subject to our disclaimer